NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

August 24, 2023 by Leave a Comment

Last Updated on August 24, 2023 by

[#item_full_content]

Spread the word

You must log in to post a comment.

We provide a balanced view on small cap biotech equities

Address : Santa Fe, New Mexico.

Generated by Feedzy

%d bloggers like this:

Reader Interactions